netFormulary NHS
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund list

08.02.04  Expand sub section  Other immunomodulating drugs
08.02.04  Expand sub section  Interferon Alfa
08.02.04  Expand sub section  Interferon beta
08.02.04  Expand sub section  Interferon gamma
08.02.04  Expand sub section  Aldesleukin to top
08.02.04  Expand sub section  BCG bladder instillation
08.02.04  Expand sub section  Canakinumab
08.02.04  Expand sub section  Dimethyl fumarate
08.02.04  Expand sub section  Fingolimod
08.02.04  Expand sub section  Glatiramer acetate to top
08.02.04  Expand sub section  Histamine
08.02.04  Expand sub section  Lenalidomide, pomalidomide, and thalidomide
08.02.04  Expand sub section  Mifamurtide
08.02.04  Expand sub section  Natalizumab
08.02.04  Expand sub section  Teriflunomide to top
Teriflunomide (Aubagio®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
  • In line with NICE 
  • Link  NICE TA303: Teriflunomide for relapsing remitting MS
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Track Changes
    Display tracking information
    click to search
    Link to adult BNF
    click to search
    Link to children's BNF
    click to search
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHS England

    Traffic Light Status Information

    Status Description

    Prescribing in children

    The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.

    The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.



    Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications.  


    Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.

    Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements.   


    Medicines for initiation and maintenance prescribing by Specialists only  


    Non-formulary medicines- medicines not recommended for routine primary care prescribing.  


    Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.